2008's ETF Winners
ETFs are gathering assets amid the market malaise.
ETFs are gathering assets amid the market malaise.
In 2008, ETFs experienced total cash inflows of approximately $160 billion, with much of the action occurring in the back half of the year when fear trumped greed and markets went into panic mode. Scott Burns, director of ETF Analysis wrote an article at the end of September discussing some theories as to why there has been such a divergence in asset flows between ETFs and their open-end mutual fund brethren. Despite the huge inflows that ETFs enjoyed during the year, assets under management still fell about 7% year over year--simply a function of the broad-based declines in the markets.
While the New Year is a perfect time to look ahead and plan accordingly for what we think is in store for 2009, we first thought it would be interesting to take a look back at 2008 to see which ETFs were the top performers in their respective categories. We also examined which funds gathered the most assets throughout the year.
Not surprisingly, the top-performing equity-focused ETFs came predominantly from funds offering exposure to the health-care and biotechnology sectors. This was to be expected as these are two classically defensive industries in which demand is relatively unaffected by the overall economic climate. In our view, health care is poised to continue performing well over the next few years and still represents a compelling value, hence our overweight position in iShares Global Health Care (IXJ) in our ETFInvestor Hands-On Portfolio. What jumps out at us is that a banking ETF made the cut for the top-five performing equity ETFs. We've highlighted just how PowerShares Dynamic Banking managed to outperform its peers by such a wide margin in our analyst report as well as in the November issue of ETFInvestor. We'd encourage interested readers to check out our analysis to get more detail on this counterintuitive top performer.
Equity ETFs | |||
2008 | 2008 Cash Inflows (MM) | AUM (MM) | |
SPDR S&P Pharmaceuticals (XPH) | -7.94 | 34.559 | 43.656 |
SPDR S&P Biotech (XBI) | -8.81 | 283.645 | 465.899 |
PowerShares Dynamic Pharmaceuticals (PJP) | -10.56 | 72.313 | 147.122 |
PowerShares Dynamic Banking | -12.58 | 77.847 | 114.987 |
iShares Nasdaq Biotechnology (IBB) | -12.68 | 229.484 | 1,475.195 |
* Data as of 12-31-2008. |
The usual suspects populated the list of top performers in the commodity complex. Precious metals (primarily gold) were the big winners among commodities, as investors fled risky assets and parked their cash in so-called safe havens. Fears of excessive inflation (down the road) probably played a role as well, considering the unprecedented level of money printing by the Federal Reserve in an attempt to rescue the ailing financial system. Morningstar ETF Strategist Paul Justice wrote an insightful piece on the use of gold as a disaster hedge that should be informative and enlightening to investors on both sides of the deflation/inflation debate. Separately, the precipitous drop in the price of energy, basic materials, and metals in the back half of the year paved the way for PowerShares DB Agriculture (DBA) to make the cut, despite posting a loss of almost 20% in 2008.
Commodity ETFs | |||
2008 | 2008 Cash Inflows (MM) | AUM (MM) | |
iShares COMEX Gold Trust (IAU) | 5.42 | 338.798 | 1,896.305 |
SPDR Gold Shares (GLD) | 2.99 | 4,658.863 | 21,691.122 |
PowerShares DB Gold | 2.83 | 39.265 | 83.663 |
PowerShares DB Precious Metals (DBP) | -2.99 | 33.877 | 77.297 |
PowerShares DB Agriculture (DBA) | -19.51 | 476.023 | 1,063.897 |
* Data as of 12-31-2008.
|
1 2 3 | Next Page >>
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.